Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006

Nana E. Tchabo, Susan McCloskey, Terry L. Mashtare, Christopher Andrews, Anurag K. Singh, Paulette Mhawech-Fauceglia, Kunle Odunsi, Shashikant Lele, Wainwright Jaggernauth

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: Optimal management of early-stage uterine papillary serous carcinoma (UPSC) remains controversial. We reviewed our outcomes in this patient population. Methods: The Roswell Park Cancer Institute (RPCI) tumor registry identified all patients with Stages I and IIA UPSC treated between January 1992 and June 2006. The Fisher's exact test was used to compare recurrence rates by adjuvant therapy received. Overall survival (OS) estimates were made using the Kaplan-Meier method. Results: Fifty-eight patients with Stage I or IIA UPSC underwent surgery. Thirty-four patients (59%) were surgically staged. Among 21 patients with Stage IA disease, 15 received adjuvant therapy. With a median follow-up of 44.7 months, only one recurrence was observed in a patient who received adjuvant brachytherapy. The 5-year OS was 66%. Among 37 patients with Stages IB-IIA, 30 patients received adjuvant therapy. With a median follow-up of 29 months, there were 7 recurrences. The 5-year OS was 60%. Although there were no significant differences in recurrence by adjuvant therapy received, a significant OS benefit was found in those who received radiation. There was no significant difference in OS distributions of those patients who received Carboplatin/Paclitaxel chemotherapy. Conclusions: Despite the limitations of our retrospective study, we have shown that even comprehensively staged early-stage UPSC patients are still at risk for recurrence despite adjuvant therapy received. Hence, all patients with this histologic diagnosis should be considered at high risk for recurrence and counseled appropriately regarding the risks and benefits of adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)249-256
Number of pages8
JournalGynecologic Oncology
Volume115
Issue number2
DOIs
StatePublished - Nov 1 2009
Externally publishedYes

Fingerprint

Papillary Carcinoma
Neoplasms
Recurrence
Survival
Therapeutics
Carboplatin
Brachytherapy
Paclitaxel
Registries
Retrospective Studies
Radiation
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Tchabo, N. E., McCloskey, S., Mashtare, T. L., Andrews, C., Singh, A. K., Mhawech-Fauceglia, P., ... Jaggernauth, W. (2009). Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006. Gynecologic Oncology, 115(2), 249-256. https://doi.org/10.1016/j.ygyno.2009.07.004
Tchabo, Nana E. ; McCloskey, Susan ; Mashtare, Terry L. ; Andrews, Christopher ; Singh, Anurag K. ; Mhawech-Fauceglia, Paulette ; Odunsi, Kunle ; Lele, Shashikant ; Jaggernauth, Wainwright. / Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006. In: Gynecologic Oncology. 2009 ; Vol. 115, No. 2. pp. 249-256.
@article{c4787d04d7894a9aa4a95f7c51fc51fa,
title = "Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006",
abstract = "Objective: Optimal management of early-stage uterine papillary serous carcinoma (UPSC) remains controversial. We reviewed our outcomes in this patient population. Methods: The Roswell Park Cancer Institute (RPCI) tumor registry identified all patients with Stages I and IIA UPSC treated between January 1992 and June 2006. The Fisher's exact test was used to compare recurrence rates by adjuvant therapy received. Overall survival (OS) estimates were made using the Kaplan-Meier method. Results: Fifty-eight patients with Stage I or IIA UPSC underwent surgery. Thirty-four patients (59{\%}) were surgically staged. Among 21 patients with Stage IA disease, 15 received adjuvant therapy. With a median follow-up of 44.7 months, only one recurrence was observed in a patient who received adjuvant brachytherapy. The 5-year OS was 66{\%}. Among 37 patients with Stages IB-IIA, 30 patients received adjuvant therapy. With a median follow-up of 29 months, there were 7 recurrences. The 5-year OS was 60{\%}. Although there were no significant differences in recurrence by adjuvant therapy received, a significant OS benefit was found in those who received radiation. There was no significant difference in OS distributions of those patients who received Carboplatin/Paclitaxel chemotherapy. Conclusions: Despite the limitations of our retrospective study, we have shown that even comprehensively staged early-stage UPSC patients are still at risk for recurrence despite adjuvant therapy received. Hence, all patients with this histologic diagnosis should be considered at high risk for recurrence and counseled appropriately regarding the risks and benefits of adjuvant therapy.",
author = "Tchabo, {Nana E.} and Susan McCloskey and Mashtare, {Terry L.} and Christopher Andrews and Singh, {Anurag K.} and Paulette Mhawech-Fauceglia and Kunle Odunsi and Shashikant Lele and Wainwright Jaggernauth",
year = "2009",
month = "11",
day = "1",
doi = "10.1016/j.ygyno.2009.07.004",
language = "English (US)",
volume = "115",
pages = "249--256",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

Tchabo, NE, McCloskey, S, Mashtare, TL, Andrews, C, Singh, AK, Mhawech-Fauceglia, P, Odunsi, K, Lele, S & Jaggernauth, W 2009, 'Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006', Gynecologic Oncology, vol. 115, no. 2, pp. 249-256. https://doi.org/10.1016/j.ygyno.2009.07.004

Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006. / Tchabo, Nana E.; McCloskey, Susan; Mashtare, Terry L.; Andrews, Christopher; Singh, Anurag K.; Mhawech-Fauceglia, Paulette; Odunsi, Kunle; Lele, Shashikant; Jaggernauth, Wainwright.

In: Gynecologic Oncology, Vol. 115, No. 2, 01.11.2009, p. 249-256.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006

AU - Tchabo, Nana E.

AU - McCloskey, Susan

AU - Mashtare, Terry L.

AU - Andrews, Christopher

AU - Singh, Anurag K.

AU - Mhawech-Fauceglia, Paulette

AU - Odunsi, Kunle

AU - Lele, Shashikant

AU - Jaggernauth, Wainwright

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Objective: Optimal management of early-stage uterine papillary serous carcinoma (UPSC) remains controversial. We reviewed our outcomes in this patient population. Methods: The Roswell Park Cancer Institute (RPCI) tumor registry identified all patients with Stages I and IIA UPSC treated between January 1992 and June 2006. The Fisher's exact test was used to compare recurrence rates by adjuvant therapy received. Overall survival (OS) estimates were made using the Kaplan-Meier method. Results: Fifty-eight patients with Stage I or IIA UPSC underwent surgery. Thirty-four patients (59%) were surgically staged. Among 21 patients with Stage IA disease, 15 received adjuvant therapy. With a median follow-up of 44.7 months, only one recurrence was observed in a patient who received adjuvant brachytherapy. The 5-year OS was 66%. Among 37 patients with Stages IB-IIA, 30 patients received adjuvant therapy. With a median follow-up of 29 months, there were 7 recurrences. The 5-year OS was 60%. Although there were no significant differences in recurrence by adjuvant therapy received, a significant OS benefit was found in those who received radiation. There was no significant difference in OS distributions of those patients who received Carboplatin/Paclitaxel chemotherapy. Conclusions: Despite the limitations of our retrospective study, we have shown that even comprehensively staged early-stage UPSC patients are still at risk for recurrence despite adjuvant therapy received. Hence, all patients with this histologic diagnosis should be considered at high risk for recurrence and counseled appropriately regarding the risks and benefits of adjuvant therapy.

AB - Objective: Optimal management of early-stage uterine papillary serous carcinoma (UPSC) remains controversial. We reviewed our outcomes in this patient population. Methods: The Roswell Park Cancer Institute (RPCI) tumor registry identified all patients with Stages I and IIA UPSC treated between January 1992 and June 2006. The Fisher's exact test was used to compare recurrence rates by adjuvant therapy received. Overall survival (OS) estimates were made using the Kaplan-Meier method. Results: Fifty-eight patients with Stage I or IIA UPSC underwent surgery. Thirty-four patients (59%) were surgically staged. Among 21 patients with Stage IA disease, 15 received adjuvant therapy. With a median follow-up of 44.7 months, only one recurrence was observed in a patient who received adjuvant brachytherapy. The 5-year OS was 66%. Among 37 patients with Stages IB-IIA, 30 patients received adjuvant therapy. With a median follow-up of 29 months, there were 7 recurrences. The 5-year OS was 60%. Although there were no significant differences in recurrence by adjuvant therapy received, a significant OS benefit was found in those who received radiation. There was no significant difference in OS distributions of those patients who received Carboplatin/Paclitaxel chemotherapy. Conclusions: Despite the limitations of our retrospective study, we have shown that even comprehensively staged early-stage UPSC patients are still at risk for recurrence despite adjuvant therapy received. Hence, all patients with this histologic diagnosis should be considered at high risk for recurrence and counseled appropriately regarding the risks and benefits of adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=70349754200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349754200&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.07.004

DO - 10.1016/j.ygyno.2009.07.004

M3 - Article

C2 - 19692115

AN - SCOPUS:70349754200

VL - 115

SP - 249

EP - 256

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -